--- title: "The board of directors of Aowei Technology, a leading company in the membrane materials segment, has approved the proposal for listing on the Beijing Stock Exchange: nearly 300 million will be raised for technological transformation, capacity expansion, and the construction of a research institute" type: "News" locale: "en" url: "https://longbridge.com/en/news/288879535.md" description: "Aowei Technology's board of directors has approved the proposal for listing on the Beijing Stock Exchange, officially entering the IPO preparation stage. The company plans to raise nearly 300 million yuan for technological transformation, capacity expansion, and research institute construction. As a leading player in the membrane materials segment, Aowei Technology's net profit attributable to the parent company is expected to exceed 86 million yuan in both 2024 and 2025, meeting the financial entry standards of the Beijing Stock Exchange. This IPO is sponsored by CSC, and the plan will be submitted for regulatory review after being approved by the shareholders' meeting" datetime: "2026-06-05T14:40:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288879535.md) - [en](https://longbridge.com/en/news/288879535.md) - [zh-HK](https://longbridge.com/zh-HK/news/288879535.md) generator: "portal-rs" --- # The board of directors of Aowei Technology, a leading company in the membrane materials segment, has approved the proposal for listing on the Beijing Stock Exchange: nearly 300 million will be raised for technological transformation, capacity expansion, and the construction of a research institute According to Tongbi Finance, the New Third Board listed company Aowei Technology (874976) will hold the 12th meeting of its second board of directors on June 5, 2026, where it will unanimously approve the proposal for a public offering of shares and listing on the Beijing Stock Exchange. The company has officially entered the substantive preparation stage for its IPO on the Beijing Stock Exchange, and the relevant listing plan will be submitted to the shareholders' meeting for review before being submitted to the Beijing Stock Exchange and the China Securities Regulatory Commission for the registration review process. According to Tongbi Finance, Hunan Aowei Technology Co., Ltd. was established in December 2014 in Zhuzhou, Hunan, and belongs to the high-performance new membrane materials sector. It is a national-level specialized and innovative key small giant and a high-tech enterprise. Its core business includes the research, development, production, sales, and supporting technical services of functional separation membrane materials and membrane components such as reverse osmosis membranes and nanofiltration membranes. The company has independently developed over 100 membrane products, covering various fields such as civil water purification, industrial ultrapure water preparation, seawater desalination, industrial wastewater resource utilization, lithium extraction from salt lakes, and municipal wastewater treatment upgrades. Its products are exported to more than 20 countries worldwide, and it holds 62 authorized patents, including 37 invention patents. Relying on three major R&D platforms, including a provincial engineering technology research center, it has achieved the industrialization of technology, breaking the monopoly of certain overseas membrane material technologies, making it one of the core domestic manufacturers of separation membranes. The lead underwriter for this IPO is CSC. From the perspective of fundamentals and financial indicators, the company's operational fundamentals are stable, and its financial data meets the stringent financial standards for listing on the Beijing Stock Exchange. According to the company's official financial report data, calculated based on the lower of the two methods before and after deducting non-recurring gains and losses, the company's net profit attributable to the parent company for 2024 is 96.7578 million yuan, with a weighted average return on net assets of 22.97%; for 2025, the net profit attributable to the parent company is 86.8115 million yuan, with a weighted average return on net assets of 17.30%. The company has achieved profitability and revenue indicators that meet the financial admission rules for public offerings on the Beijing Stock Exchange for two consecutive complete accounting years. In 2025, the company achieved operating revenue of 481 million yuan, supported by industry prosperity and the trend of domestic substitution, ensuring the company's stable operation. The details of this public offering plan have been announced in the board meeting announcement. The company plans to issue new shares to unspecified qualified investors on the Beijing Stock Exchange, with an initial issuance limit of 42.96 million shares (with a par value of 1 yuan per share). The issuance process may utilize an over-allotment option, with the over-allotment shares not exceeding 15% of the initial issuance amount, which is 6.444 million shares. After fully exercising the green shoe option, the total number of shares issued may reach a maximum of 49.404 million shares. All shares issued in this offering will be new shares, and existing shareholders will not participate in the sale of old shares. The issuance pricing may adopt one of three models: self-negotiated pricing, online bidding, or offline inquiry pricing. The final pricing rules will be executed by the board of directors authorized by the shareholders' meeting in conjunction with the underwriting institutions in accordance with regulatory requirements. The issuance will adopt a balance underwriting model by the lead underwriter CSC. On the fundraising side, the company plans to invest all the raised funds, after deducting issuance costs, into two major physical projects, with a total project investment amount of 322.2156 million yuan, of which 299.8620 million yuan is planned to be used for the projects. Among them, the high-performance functional membrane material technology transformation and expansion construction project plans to invest 239.3905 million yuan, and the Aowei Technology Innovation Research Institute construction project will use the entire raised funds of 60.4716 million yuan If the actual fundraising cannot cover the total investment of the project, the funding gap will be supplemented by the company itself; any idle surplus funds from the fundraising will be used in accordance with regulatory procedures, and the company allows for the replacement of early project self-raised advance payments with the raised funds. After the project is implemented, on one hand, it will expand the company's core membrane product production capacity, and on the other hand, it will improve the hardware support for cutting-edge membrane material research and development, strengthening the company's medium and long-term technological iteration capabilities and consolidating the competitive advantage of domestic membrane material leaders. Regarding profit distribution, the undistributed profits accumulated before the listing will be shared by new and old shareholders according to the latest shareholding ratio after the issuance; after the completion of this issuance, the company's stock will be listed on the Beijing Stock Exchange, while simultaneously terminating its listing on the National Equities Exchange and Quotations. The resolutions related to this listing will be valid for 12 months from the date of approval by the shareholders' meeting. If the project successfully passes the review of the Beijing Stock Exchange and the registration of the China Securities Regulatory Commission, the validity period of the resolution will be extended until the initial public offering is completed, and the final listing plan will be subject to the approval content of the China Securities Regulatory Commission. The company also reminds investors of the risks: the application for this IPO on the Beijing Stock Exchange carries uncertainties regarding the failure to pass the listing review by the Beijing Stock Exchange and the registration approval by the China Securities Regulatory Commission, which poses market risks of issuance failure and inability to timely list on the Beijing Stock Exchange. Currently, the company does not have any circumstances prohibited from listing as specified in the Beijing Stock Exchange listing rules, and all preparatory work is progressing steadily. Subsequent steps include completing the shareholders' meeting vote, inquiries and reviews by the Beijing Stock Exchange, and registration with the China Securities Regulatory Commission, among other statutory processes ### Related Stocks - [06066.HK](https://longbridge.com/en/quote/06066.HK.md) - [601066.CN](https://longbridge.com/en/quote/601066.CN.md) ## Related News & Research - [Medtide proposes bylaw changes to allow board size range of five to nine directors](https://longbridge.com/en/news/297149727.md) - [Wedbush Delivers Blunt Message on Nvidia Stock Ahead of Earnings](https://longbridge.com/en/news/296948993.md) - [Zhipu identifies Ox Alpha as GLM-5.3-Flash and releases model weights](https://longbridge.com/en/news/297138298.md) - [CITIC BANK Interim Net Profit Rises 3.1% YoY to RMB37.6 billion; Interim DPS RMB2.03 per 10 Shares](https://longbridge.com/en/news/297065142.md) - [Perennial Energy Holdings (SEHK:2798) Stock Faces Valuation Reckoning After Return To Losses](https://longbridge.com/en/news/297044009.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**